Teratogenicity and Pregnancy Categories
Certain drugs cause birth defects when used during pregnancy. Understanding teratogenic risk periods, mechanisms, and classification systems guides safer prescribing.
## Overview
Teratogenicity refers to the ability of a drug or substance to cause structural or functional abnormalities in a developing embryo or fetus. Approximately 2-3% of birth defects are attributed to drug exposure. Because pregnant women are excluded from most clinical trials, teratogenicity data often comes from animal studies, case reports, and registries.
## Critical Periods of Vulnerability
**Weeks 1-2 (pre-implantation)**: The "all-or-none" period. Toxic exposure either destroys the embryo (miscarriage) or is fully repaired by pluripotent cells. Malformations are rare during this period.
**Weeks 3-8 (organogenesis)**: The highest-risk period. Major organ systems are forming, and exposure to teratogens during specific windows causes characteristic malformations. Neural tube closure (weeks 3-4), heart septation (weeks 3-6), and limb formation (weeks 4-8) are particularly vulnerable.
**Weeks 9-40 (fetal period)**: Organs are growing and maturing. Teratogenic exposure primarily affects growth and functional development rather than causing structural malformations. CNS development continues throughout pregnancy, making it vulnerable to neurobehavioral teratogens.
## Known Human Teratogens
- **Thalidomide**: Limb reduction defects (phocomelia). Led to modern drug safety regulations.
- **Isotretinoin**: Craniofacial, cardiac, and CNS malformations. Requires iPLEDGE program.
- **Valproic acid**: Neural tube defects (1-2% risk), craniofacial abnormalities, neurodevelopmental impairment.
- **Warfarin**: Nasal hypoplasia, stippled epiphyses (first trimester). CNS abnormalities (any trimester).
- **Methotrexate**: Aminopterin syndrome (cranial defects, limb abnormalities). Contraindicated.
- **ACE inhibitors/ARBs**: Renal agenesis, oligohydramnios, pulmonary hypoplasia (second/third trimester).
- **Lithium**: Ebstein anomaly (cardiac, though risk lower than initially estimated at ~0.1%).
- **Alcohol**: Fetal alcohol spectrum disorders (most common preventable cause of intellectual disability).
## Classification Systems
The **former FDA categories** (A, B, C, D, X) were replaced in 2015 by the **Pregnancy and Lactation Labeling Rule (PLLR)**, which provides narrative sections on pregnancy, lactation, and females/males of reproductive potential. The PLLR offers more nuanced risk communication but requires clinical interpretation rather than simple letter grades.
**Category X** (contraindicated) drugs included isotretinoin, thalidomide, methotrexate, and warfarin. The concept persists in practice even though the letter system is phased out.
## Risk Assessment
Teratogenic risk depends on timing, dose, duration, genetic susceptibility, and concurrent exposures. Not all exposures result in malformations. Baseline birth defect rate is 3-5% regardless of drug exposure, which provides important context for risk counseling.
## Key Takeaways
- Weeks 3-8 (organogenesis) is the highest-risk period for structural malformations
- Isotretinoin, valproic acid, warfarin, and methotrexate are well-established teratogens
- The PLLR replaced letter categories with narrative risk descriptions in 2015
- ACE inhibitors are safe in the first trimester but contraindicated thereafter
- Pre-conception counseling and medication review are essential for women of childbearing potential